Post
Patient enrollment is open for a pivotal/Phase III clinical trial to test GID BIO’s cellular therapy for knee osteoarthritis GID BIO’s point-of-care cellular therapy is being tested to treat...
Patient enrollment is open for a pivotal/Phase III clinical trial to test GID BIO’s cellular therapy for knee osteoarthritis GID BIO’s point-of-care cellular therapy is being tested to treat...
Shrock Clinical Research, the only approved site in Florida, joins GID BIO’s pivotal, FDA-compliant clinical trial for knee osteoarthritis Kevin Shrock, MD, FAAOS, CPI, a South Florida practicing orthopaedic...
Statements in this article are the perspective of the San Antonio Business Journal.
Jaime Garza drives innovation in Texas as principal investigator of a pivotal/Phase III trial for GID BIO’s cellular therapy As the number of companies developing and producing medical devices rises...
Patient enrollment begins at Tulane University School of Medicine for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis Jaime Garza, MD, DDS, FACS, Professor of Orthopaedics,...
New Jersey Regenerative Institute begins enrolling patients for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis Gerry Malanga, M.D., recent president of Interventional Orthobiologics Foundation, is...
GID BIO begins pivotal/Phase III clinical trial patient enrollment process at Texas Center for Cell Therapy and Research in San Antonio This summer, the FDA cleared our stromal-vascular-fraction cellular therapy...
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to treat hospitalized COVID-19 patients applies...
Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements” As the total number of confirmed COVID-19 cases surpasses five million...
Statements in this article are the perspective of the Denver Business Journal.
Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee LOUISVILLE, Colo., July 28, 2020 -- Roy J. Bostock, former Chairman...
The Tulane University Department of Orthopedics is testing a potential cellular therapy treatment for one of the world’s most common, disabling, painful musculoskeletal conditions, osteoarthritis. In New Orleans WWL-TV announced...